Payment overview · 2025
General Payments
$253.59
16 reported records · 10 companies
Healthcare provider profile · identity verified
Stanley C Gallagher, DO
Allopathic & Osteopathic Physicians|Family Medicine · SISSETON, SD · NPI 1831125657
Verified facts
What the public records show
CMS Open Payments records show Stanley C Gallagher, DO received $253.59 in general payments during 2025 across 16 reported records.
Phathom Pharmaceuticals, Inc. accounted for 24.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $61.78 | 24.4% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.21 | 13.1% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $31.11 | 12.3% | 2 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $22.46 | 8.9% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $20.46 | 8.1% | 1 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $20.12 | 7.9% | 1 | 2025 |
| Pelvital USA, Inc. | Unresolved — no canonical attribution shown | $18.74 | 7.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.81 | 6.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.71 | 5.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.19 | 5.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $253.59 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $61.78 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.21 | 2 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $31.11 | 2 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $31.11 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka Pharmaceutical Development & Commercialization, Inc. | $22.46 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.81 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.81 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 164 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
142 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
164 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 797 | 151 |
| Furosemide | Furosemide | 738 | 139 |
| Amlodipine Besylate | Amlodipine Besylate | 683 | 145 |
| Atorvastatin Calcium | Atorvastatin Calcium | 659 | 135 |
| Pantoprazole Sodium | Pantoprazole Sodium | 616 | 131 |
| Gabapentin | Gabapentin | 555 | 87 |
| Losartan Potassium | Losartan Potassium | 514 | 106 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 502 | 369 |
| Lisinopril | Lisinopril | 500 | 95 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 460 | 459 |
| Metoprolol Succinate | Metoprolol Succinate | 451 | 83 |
| Diclofenac Sodium | Diclofenac Sodium | 449 | 100 |
| Omeprazole | Omeprazole | 348 | 67 |
| Potassium Chloride | Potassium Chloride | 340 | 71 |
| Finasteride | Finasteride | 310 | 64 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 296 | 55 |
| Simvastatin | Simvastatin | 286 | 56 |
| Tramadol Hcl | Tramadol Hcl | 285 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 228 | 45 |
| Metformin Hcl | Metformin Hcl | 221 | 46 |
| Sertraline Hcl | Sertraline Hcl | 212 | 37 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 197 | 197 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 183 | 40 |
| Donepezil Hcl | Donepezil Hcl | 170 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 41 |
| Eliquis | Apixaban | 164 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 164 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 146 | 26 |
| Carvedilol | Carvedilol | 145 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 145 | 28 |
| Jardiance | Empagliflozin | 142 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 142 | 25 |
| Lorazepam | Lorazepam | 141 | 31 |
| Trazodone Hcl | Trazodone Hcl | 141 | 29 |
| Alprazolam | Alprazolam | 137 | 24 |
| Allopurinol | Allopurinol | 135 | 31 |
| Xarelto | Rivaroxaban | 133 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 129 | 26 |
| Mresvia | Rsv Vaccine, Pref, Mrna/Pf | 124 | 124 |
| Glipizide Er | Glipizide | 119 | 28 |
| Prednisone | Prednisone | 116 | 50 |
| Irbesartan | Irbesartan | 115 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 31 |
| Meloxicam | Meloxicam | 106 | 16 |
| Cephalexin | Cephalexin | 104 | 77 |
| Digoxin | Digoxin | 104 | 17 |
| Fentanyl | Fentanyl | 104 | 14 |
| Montelukast Sodium | Montelukast Sodium | 100 | 22 |
| Buspirone Hcl | Buspirone Hcl | 94 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 92 | 43 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 89 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 89 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 87 | 13 |
| Ezetimibe | Ezetimibe | 83 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 83 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 20 |
| Warfarin Sodium | Warfarin Sodium | 81 | suppressed |
| Myrbetriq | Mirabegron | 80 | suppressed |
| Pregabalin | Pregabalin | 79 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 16 |
| Sucralfate | Sucralfate | 70 | 18 |
| Levofloxacin | Levofloxacin | 69 | 55 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 11 |
| Januvia | Sitagliptin Phosphate | 67 | 13 |
| Ozempic | Semaglutide | 66 | 11 |
| Metformin Hcl Er | Metformin Hcl | 65 | 16 |
| Glipizide | Glipizide | 64 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 62 | 48 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 62 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 19 |
| Famotidine | Famotidine | 58 | suppressed |
| Mirtazapine | Mirtazapine | 57 | 14 |
| Alendronate Sodium | Alendronate Sodium | 55 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 54 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 53 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 51 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 51 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 50 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | suppressed |
| Azithromycin | Azithromycin | 47 | 44 |
| Bupropion Xl | Bupropion Hcl | 47 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 47 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 44 | suppressed |
| Mupirocin | Mupirocin | 43 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 43 | suppressed |
| Spironolactone | Spironolactone | 42 | suppressed |
| Atenolol | Atenolol | 41 | 14 |
| Baclofen | Baclofen | 41 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 40 | 11 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 40 | 40 |
| Valacyclovir | Valacyclovir Hcl | 40 | 12 |
| Diazepam | Diazepam | 38 | 12 |
| Methotrexate | Methotrexate Sodium | 37 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 36 | suppressed |
| Verapamil Er | Verapamil Hcl | 36 | suppressed |
| Celecoxib | Celecoxib | 35 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Indomethacin | Indomethacin | 34 | 23 |
| Humalog | Insulin Lispro | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 32 | suppressed |
| Amoxicillin | Amoxicillin | 31 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Jantoven | Warfarin Sodium | 29 | 11 |
| Nitroglycerin | Nitroglycerin | 29 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 11 |
| Vraylar | Cariprazine Hcl | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 25 | 21 |
| Fluconazole | Fluconazole | 25 | 20 |
| Megestrol Acetate | Megestrol Acetate | 24 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Calcitriol | Calcitriol | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 23 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 22 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Erythromycin | Erythromycin Base | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Cefadroxil | Cefadroxil | 20 | 17 |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 17 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Letrozole | Letrozole | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Budesonide | Budesonide | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Tobramycin | Tobramycin | 14 | 11 |
| Torsemide | Torsemide | 14 | suppressed |
| Dexamethasone | Dexamethasone | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Monoject Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Bacitracin-Polymyxin | Bacitracin/Polymyxin B Sulfate | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | 11 |
| Haloperidol | Haloperidol | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $253.59 · 16 records | Phathom Pharmaceuticals, Inc. | CAPLYTA, ELIQUIS, MONOFERRIC, MOUNJARO, NURTEC ODT, OPSUMIT, REXULTI, SMARTVEST, The Cologuard Plus Collection Kit, UPTRAVI, VOQUEZNA, ZAVZPRET, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error